VHCP Management, LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+6,558
(3.5%)
New positions
4
Sold out positions
5
Turnover %
26.6%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| HRTX | 15,242 | NEW |
| GW PHARMACEUTICALS PLC | 9,205 | 31.7% |
| FLAMEL TECHNOLOGIES SA | 6,700 | NEW |
| BCRX | 5,122 | 38.4% |
| ANACOR PHARMACEUTICALS INC | 4,993 | 19.2% |
| DBV Technologies | 4,804 | 66.9% |
| KERYX BIOPHARMACEUTICALS | 4,091 | 31.6% |
| XNCR | 1,037 | NEW |
| TXMD | 931 | 21.1% |
| VERSARTIS INC | 571 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| AP PHARMA INC COM STK | -9,862 | -100.0% |
| IRWD | -9,810 | -46.9% |
| VNDA | -8,924 | -100.0% |
| T | -3,890 | -100.0% |
| CHELSEA THERAPEUTICS INTL LT | -3,193 | -42.3% |
| Biodel Inc. | -2,728 | -100.0% |
| HYPERION THERAPEUTICS INC | -2,209 | -100.0% |
| OCERA THERAPEUTICS INC | -1,717 | -18.8% |
| NBIX | -1,604 | -24.7% |
| DYAX CORP | -1,525 | -7.8% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|